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Erythropoietin (EPO) is of immense practical clinical utility in the treatment of anemia, and insight into 
EPO-regulated signaling pathways may reveal new targets for the treatment of dysregulated erythropoiesis. 
While significant headway has been made in understanding the intracellular signals mediating the effects of 
EPO through the homodimeric EPO receptor (EPOR), we clearly don’t know all the intracellular mediators 
involved. In this issue, Verma et al. report a novel mediator of EPO-dependent expansion of human 
erythroid progenitor cells and development of erythroblasts, which they have named regulator of human 
erythroid cell expansion (RHEX).
Applying a global phosphotyrosine (PY) phosphoproteomic approach, the authors identified an un-
characterized 26K open reading frame that was rapidly and highly tyrosine-phosphorylated at two sites 
after EPO stimulation. RHEX has no significant homology with known proteins and, although well-
conserved in humans and other primates, it is not found in the genomes of rats, mice, or lower vertebrates. RHEX knock-
down in an EPO-dependent human cell line attenuated cell growth and activation of ERK1 and ERK2, with no effect on 
cell death. In purified populations of human erythroid progenitor cells, RHEX knockdown delayed the formation of maturing 
erythroblasts. Coimmunoprecipitation experiments indicated that RHEX associates with the versatile adaptor protein GRB2 
following EPO stimulation.
This outstanding paper opens up a number of important questions regarding the function of RHEX and the regulation of 
EPOR signaling. Is RHEX involved in the intracellular signaling of other cytokines? If so, does EPO signaling compete with 
other cytokine signaling pathways for GRB2 binding to RHEX? In addition to the homodimeric EPOR, a heterodimeric 
EPOR (EPOR chain and CD131, the common b-chain of GM-CSFR and IL-3R), which is present on some normal and 
cancer cell types, mediates nonerythro-
poietic effects of EPO. Is RHEX also 
an intermediary in signaling through 
the heterodimeric EPOR? Finally, it is 
of interest that RHEX was not de-
tected in rats, mice, and lower verte-
brates. Why is this? And how does 
EPO–EPOR signaling differ in differ-
ent species?
Although the investigators chose 
to focus on RHEX, their PY-phos-
phoproteomic analysis identified other 
EPO-induced candidate targets, in-
cluding molecular adaptors, serine/
threonine kinases, tyrosine phos-
phatases, ubiquitin factors, and cell 
cycle regulators, that should provide 
for continued productive analysis of 
EPO-induced signaling. The EPO–
EPOR signaling gray box is opening 
up, and with it will come greater insight 
into EPO’s actions and its modulation 
for clinical advantage.
Verma, R., et al. 2014. J. Exp. Med. http://dx 
.doi.org/10.1084/jem.20130624.
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The illness that follows influenza A virus (IAV) infection results from both direct effects of 
IAV replication in the respiratory tract (RT) and from sequelae of the host immune re-
sponse. The virus directly induces apoptosis or necrosis of infected RT cells and NK cells, 
CD8 T cells lyse infected cells, and damaging inflammatory mediators are produced by vari-
ous infiltrating immune cells. Accordingly, the degree of RT pathology is believed to reflect 
both the extent of virus replication and the magnitude of the host immune response. In this 
issue, however, Heaton et al. provide evidence for a novel mechanism of IAV pathogenesis. 
They find that a small fraction of a particular RT cell type, the club cell, can “cure” itself of 
IAV but continue to produce inflammatory mediators, which may contribute to sustained 
RT inflammation and injury following IAV clearance.
Heaton et al. adapted a strategy to indelibly mark IAV-
infected cells where any cell infected by the virus will express 
RFP. Contrary to expectation, they detected RFP+ cells in 
the RT up to day 21 post-infection (p.i.), long after virus-
infected cells are cleared. The authors identify these residual 
RFP+ cells as club cells—bronchiolar (small airway) exo-
crine cells (formerly known as Clara cells), which secrete 
products that protect the small airways.
Remarkably, by day 10 p.i. the residual RFP+ club cells 
were “cured,” that is, they no longer expressed detectable 
viral RNA. But they retained the type I interferon stimu-
lated gene expression signature of infected cells and pro-
duction of inflammatory chemokines, suggesting that these 
cells may contribute to RT pathology. Supporting this idea, 
selective depletion of the residual RFP+ cells diminished 
epithelial cell damage in the RT. However, severe RT 
injury with lethal outcome is associated with infection of 
alveolar epithelial cells, which are not “cured” in this 
model, so the contribution of club cells in IAV pathogenesis 
remains to be determined.
These provocative findings raise many questions, notably, 
how do infected club cells escape destruction by IAV and 
recognition by NK cells or CD8 CTL? Also, what sustains 
the inflammatory signature of club cells after viral RNA 
elimination? Nevertheless, these results provide a potential 
explanation for persistent RT inflammation following virus 
clearance and may presage the development of new strategies 
to treat the sequelae of IAV infection.
Heaton, N.S., et al. 2014. J. Exp. Med. http://dx.doi.org/10.1084/jem.20140488.
IAV replicates primarily in the respiratory tract epithelium, resulting 
in cell death via direct- or immune-mediated lysis (A). A small fraction 
of club cells can “cure” themselves of IAV but continue to produce 
interferon-stimulated gene (ISG) products (B).
Influenza pathogenesis: Club cells take the “cure”
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